Develops and commercializes innovative therapeutics and pharmaceutical products for oncology and other unmet medical needs.
CASI Pharmaceuticals, Inc., a dynamic biopharmaceutical company headquartered in Rockville, Maryland, focuses on developing and commercializing innovative therapeutics and pharmaceutical products across global markets including China and the United States. The company is renowned for EVOMELA, an intravenous melphalan formulation used as a conditioning treatment before stem cell transplantation and as a palliative therapy for multiple myeloma patients. CASI's extensive product pipeline features cutting-edge candidates such as CNCT19, an autologous CD19 CAR-T therapy under investigation for treating B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL).
The company's research efforts also include BI-1206, currently in Phase I/II trials in combination with Keytruda for solid tumors and rituximab (MabThera) for relapsed/refractory NHL. Additionally, CASI is advancing CB-5339 through Phase I trials targeting acute myeloid leukemia and myelodysplastic syndrome. Its diverse pipeline further encompasses CID-103 for multiple myeloma treatment, Thiotepa for various stem cell transplants, and long-acting injectable formulations of Octreotide for acromegaly and neuroendocrine tumors. CASI operates under strategic licensing agreements with Juventas Cell Therapy Ltd., BioInvent International AB, Black Belt Therapeutics Limited, and Cleave Therapeutics, Inc., in addition to distribution agreements with leading pharmaceutical entities like China Resources Pharmaceutical Commercial Group International Trading Co., Ltd., Pharmathen Global BV, and Riemser Pharma GmbH.
Founded in 1991 as EntreMed, Inc. and rebranded as CASI Pharmaceuticals, Inc. in 2014, the company continues to innovate and expand its global footprint in the biopharmaceutical industry. CASI Pharmaceuticals is committed to advancing novel therapies that address significant unmet medical needs, thereby enhancing treatment options and improving patient outcomes worldwide.